Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III neoadjuvant breast cancer program with bevacizumab, everolimus, and lapatinib
2006-005834-19Phase 3Completed
- Sponsor
- GBG Forschungs
- Start
- Feb 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab, everolimus and lapatinib in breast cancer (2 arms), sponsored by GBG Forschungs. Primary endpoint: Pathological complete response of breast and lymph nodes. Started Feb 2007; status: completed.
02
Drugs
bevacizumabeverolimuslapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-005834-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005834-19.